Literature DB >> 17293264

Preprocedure hyperglycemia is more strongly associated with restenosis in diabetic patients after percutaneous coronary intervention than is hemoglobin A1C.

Joseph Lindsay1, Arvind K Sharma, Daniel Canos, Mohan Nandalur, Ellen Pinnow, Sue Apple, Giacomo Ruotolo, Mevan Wijetunga, Ron Waksman.   

Abstract

BACKGROUND: Although more frequent in diabetic patients, restenosis after percutaneous coronary intervention (PCI) is less common in those with good glycemic control. High circulating insulin levels may also be associated with more frequent restenosis.
METHODS: Fasting blood samples were obtained from 162 diabetic patients immediately prior to the PCI and analyzed for glucose, hemoglobin A1C, and insulin. Nine-month follow-up information was obtained in 145 (89.5%) patients. Target vessel revascularization (TVR) was the surrogate for restenosis.
RESULTS: Patients were divided into quartiles with regard to their blood levels. Insulin, calculated insulin resistance, and hemoglobin A1C were not associated with increased TVR rates. Glucose level was significantly associated (P=.02). Patients in the two lower quartiles (glucose < or = 128 mg/dl) had a 9-month TVR rate of 12.7% while those in the two higher quartiles (>128 mg/dl) had a rate of 33.8% (P=.005). Level of glucose was independent of hemoglobin A1C. In patients whose A1C level was < or = 7%, the TVR rate was greater in those with a glucose level >128 mg/dl (39.1% vs. 10.6%, P=.009). Similarly, in patients with a hemoglobin A1C level >7%, the TVR rate was lower in patients with a glucose level < or = 128 mg/dl, but this difference did not reach statistical significance (16.6% vs. 31.3%, P=.3).
CONCLUSIONS: Hemoglobin A1C, insulin, and insulin resistance at the time of the PCI are not associated with restenosis. Periprocedural hyperglycemia may promote restenosis in diabetics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17293264     DOI: 10.1016/j.carrev.2006.10.002

Source DB:  PubMed          Journal:  Cardiovasc Revasc Med        ISSN: 1878-0938


  6 in total

1.  Investigation Into the Risk Factors Related to In-stent Restenosis in Elderly Patients With Coronary Heart Disease and Type 2 Diabetes Within 2 Years After the First Drug-Eluting Stent Implantation.

Authors:  Ming Yi; Wen-Hui Tang; Shuai Xu; Xiao Ke; Qiang Liu
Journal:  Front Cardiovasc Med       Date:  2022-05-20

2.  Association of elevated fasting glucose with lower patency and increased major adverse limb events among patients with diabetes undergoing infrapopliteal balloon angioplasty.

Authors:  Satinder Singh; Ehrin J Armstrong; Walid Sherif; Bejan Alvandi; Gregory G Westin; Gagan D Singh; Ezra A Amsterdam; John R Laird
Journal:  Vasc Med       Date:  2014-06-17       Impact factor: 3.239

3.  Recurrence of Critical Limb Ischemia After Endovascular Intervention in Patients with Diabetic Foot Ulcers.

Authors:  Marco Meloni; Valentina Izzo; Laura Giurato; Costantino Del Giudice; Valerio Da Ros; Valerio Cervelli; Roberto Gandini; Luigi Uccioli
Journal:  Adv Wound Care (New Rochelle)       Date:  2018-06-01       Impact factor: 4.730

4.  Glycemic Control in Coronary Revascularization.

Authors:  Francisco Ujueta; Ephraim N Weiss; Steven P Sedlis; Binita Shah
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-02

5.  Glycosylated hemoglobin (HbA1c) levels and clinical outcomes in diabetic patients following coronary artery stenting.

Authors:  Seyed Ebrahim Kassaian; Hamidreza Goodarzynejad; Mohammad Ali Boroumand; Mojtaba Salarifar; Farzad Masoudkabir; Mohammad Reza Mohajeri-Tehrani; Hamidreza Pourhoseini; Saeed Sadeghian; Narges Ramezanpour; Mohammad Alidoosti; Elham Hakki; Soheil Saadat; Ebrahim Nematipour
Journal:  Cardiovasc Diabetol       Date:  2012-07-17       Impact factor: 9.951

Review 6.  Association Between Glycosylated Hemoglobin Level and Cardiovascular Outcomes in Diabetic Patients After Percutaneous Coronary Intervention.

Authors:  Jia Zheng; Jing Cheng; Qian Zhang; Cuijuan Qi; Tong Wang; Xinhua Xiao
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.